-
平臺(tái)編號(hào)：bio-68437
-
國(guó)際編號(hào)：CRL-1910?
-
細(xì)胞信息： M/K-1.9
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
M/K-1.9
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
ATCC Number：CRL-1910?
數(shù)量：大量
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
是否是腫瘤細(xì)胞：0
物種來(lái)源：大鼠
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.1ml Designations: M/K-1.9
Depositors: ?PW Kincade
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against murine VCAM-1
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:1. This hybridoma is provided for research purposes only. Neither the cell line nor the antibody derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2. Any proposed commercial use of these cells or antibody produced from them must first be negotiated with the Oklahoma Medical Research Foundation, 825 N.E. 13th, Oklahoma City, OK 73104. Telephone (405) 271-7905.
Tumorigenic:Yes
Comments:Animals were immunized with stromal cells from mouse bone marrow.
Spleen cells were fused with Sp2/0 myeloma cells.
The antibody blocks adhesion of lymphocyte precursors to bone marrow stromal cells.
The antibody recognizes an antigen believed to be the mouse equivalent of human VCAM-1 that is expressed on bone marrow stromal cells and on inflamed endothelial cells (see also M/K-2.7, ATCC CRL-1909 ).
Propagation: ATCC complete growth medium: RPMI 1640 medium with 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
Subculturing: Medium Renewal: Every 2 to 4 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 1 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
References: 22803: Miyake K, et al. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J. Cell Biol. 114: 557-565, 1991. PubMed: 1713592
22824: Miyake K, et al. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J. Exp. Med. 173: 599-607, 1991. PubMed: 1997648
ATCC Number：CRL-1910?
數(shù)量：大量
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG1; kappa light chain
是否是腫瘤細(xì)胞：0
物種來(lái)源：大鼠
運(yùn)輸方式：凍存運(yùn)輸
規(guī)格：0.1ml Designations: M/K-1.9
Depositors: ?PW Kincade
Isotype: IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against murine VCAM-1
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:1. This hybridoma is provided for research purposes only. Neither the cell line nor the antibody derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purpose of sale, or producing for sale, cells or their products. The cells are provided as a service to the research community. They are provided without warranty or merchantability of fitness for a particular purpose or any other warranty, express or implied. 2. Any proposed commercial use of these cells or antibody produced from them must first be negotiated with the Oklahoma Medical Research Foundation, 825 N.E. 13th, Oklahoma City, OK 73104. Telephone (405) 271-7905.
Tumorigenic:Yes
Comments:Animals were immunized with stromal cells from mouse bone marrow.
Spleen cells were fused with Sp2/0 myeloma cells.
The antibody blocks adhesion of lymphocyte precursors to bone marrow stromal cells.
The antibody recognizes an antigen believed to be the mouse equivalent of human VCAM-1 that is expressed on bone marrow stromal cells and on inflamed endothelial cells (see also M/K-2.7, ATCC CRL-1909 ).
Propagation: ATCC complete growth medium: RPMI 1640 medium with 0.05 mM 2-mercaptoethanol, 90%; fetal bovine serum, 10%
Subculturing: Medium Renewal: Every 2 to 4 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 1 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
References: 22803: Miyake K, et al. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J. Cell Biol. 114: 557-565, 1991. PubMed: 1713592
22824: Miyake K, et al. Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis. J. Exp. Med. 173: 599-607, 1991. PubMed: 1997648
